WOLFGANG WINKELMAYER to Hypoglycemic Agents
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Hypoglycemic Agents.
Connection Strength
1.869
-
Black Race Coefficient in GFR Estimation and Diabetes Medications in CKD: National Estimates. J Am Soc Nephrol. 2021 06 01; 32(6):1319-1321.
Score: 0.570
-
Guideline-conformity of initiation with oral hypoglycemic treatment for patients with newly therapy-dependent type 2 diabetes mellitus in Austria. Pharmacoepidemiol Drug Saf. 2011 Jan; 20(1):57-65.
Score: 0.277
-
Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med. 2008 Nov 24; 168(21):2368-75.
Score: 0.242
-
Cardiovascular risk and the thiazolidinediones: d?j? vu all over again? JAMA. 2007 Sep 12; 298(10):1216-8.
Score: 0.223
-
Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study. Sci Rep. 2020 04 06; 10(1):5964.
Score: 0.133
-
Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease. J Diabetes Complications. 2019 11; 33(11):107423.
Score: 0.128
-
Prevalence and determinants of unintended double medication of antihypertensive, lipid-lowering, and hypoglycemic drugs in Austria: a nationwide cohort study. Pharmacoepidemiol Drug Saf. 2016 Jan; 25(1):90-9.
Score: 0.097
-
Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study. Appl Health Econ Health Policy. 2015 Apr; 13(2):193-205.
Score: 0.094
-
Medication issues in older individuals with CKD. Adv Chronic Kidney Dis. 2010 Jul; 17(4):320-8.
Score: 0.068
-
Cardiovascular outcomes associated with prescription of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with diabetes and chronic kidney disease. Diabetes Obes Metab. 2022 05; 24(5):928-937.
Score: 0.038